Yasuhiro Gotô

ORCID: 0000-0003-2235-8567
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Lung Cancer Treatments and Mutations
  • Advanced ceramic materials synthesis
  • Cancer Immunotherapy and Biomarkers
  • Advanced MRI Techniques and Applications
  • Lung Cancer Research Studies
  • Lung Cancer Diagnosis and Treatment
  • Colorectal Cancer Treatments and Studies
  • Aluminum Alloys Composites Properties
  • Cardiac Imaging and Diagnostics
  • Medical Imaging and Pathology Studies
  • Hippo pathway signaling and YAP/TAZ
  • Gastric Cancer Management and Outcomes
  • Pancreatic and Hepatic Oncology Research
  • PARP inhibition in cancer therapy
  • Advanced materials and composites
  • Ubiquitin and proteasome pathways
  • Occupational and environmental lung diseases
  • Tracheal and airway disorders
  • Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
  • MRI in cancer diagnosis
  • Pneumonia and Respiratory Infections
  • Epigenetics and DNA Methylation
  • Advanced Neuroimaging Techniques and Applications
  • Metal and Thin Film Mechanics
  • Cardiovascular Function and Risk Factors

Fujita Health University
2015-2025

Nobuhara Hospital
2025

Fujita Health University Hospital
2015-2024

National Cancer Center
2024

Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori
2024

Istituti di Ricovero e Cura a Carattere Scientifico
2024

Tokyo Women's Medical University Hospital
2018-2024

Beppu Medical Center
2023-2024

Nagoya University
1989-2022

Kyushu University
2004-2022

Rationale: Identification of patients with drug-resistant pathogens at initial diagnosis is essential for treatment pneumonia.Objectives: To elucidate clinical features community-acquired pneumonia (CAP) and healthcare-associated (HCAP), to clarify risk factors in CAP HCAP.Methods: A prospective observational study was conducted hospitalized 10 institutions Japan. Pathogens identified as not susceptible ceftriaxone, ampicillin-sulbactam, macrolides, respiratory fluoroquinolones were defined...

10.1164/rccm.201301-0079oc article EN American Journal of Respiratory and Critical Care Medicine 2013-07-15

The cellular interactions in the tumor microenvironment of colorectal cancer (CRC) are poorly understood, hindering patient treatment. In current study, we investigate whether events occurring at invasion front particular importance for CRC treatment strategies. To this end, analyze tissues by combining spatial transcriptomics from patients with a public single-cell transcriptomic atlas to determine cell-cell front. We show that cells localized specifically These induce human leukocyte...

10.1016/j.celrep.2022.111929 article EN cc-by-nc-nd Cell Reports 2023-01-01

A novel 3.6-kb cDNA, IA-2, with a 2,937-bp open reading frame was isolated from human insulinoma subtraction library (ISL-153). The predicted amino acid sequence and in vitro-translated product of IA-2 cDNA revealed 979-amino-acid protein pI value 7.09 molecular mass 105,847 daltons. is consistent signal peptide, an extracellular domain, transmembrane region, intracellular domain. domain contains unusual cysteine-rich region following the peptide. cytoplasmic possesses highly conserved...

10.1089/dna.1994.13.505 article EN DNA and Cell Biology 1994-05-01

10.1023/a:1017946518955 article EN Journal of Materials Science 2001-01-01

Recent advances in bronchoscopy, such as transbronchial biopsy (TBB) using endobronchial ultrasonography with a guide sheath (EBUS-GS), have improved the diagnostic yield of small-sized peripheral lung lesions. In some cases, however, it is difficult to obtain adequate samples for pathological diagnosis. Adequate prediction accuracy TBB EBUS-GS important before deciding whether bronchoscopy should be performed.We retrospectively reviewed 149 consecutive patients who underwent lesions (≤30 mm...

10.1186/s12880-015-0060-5 article EN cc-by BMC Medical Imaging 2015-06-19

IntroductionWe aimed to evaluate the efficacy and safety of nanoparticle albumin-bound (nab-) paclitaxel for previously treated patients with advanced NSCLC.MethodsIn this randomized, open-label, noninferiority phase 3 trial, we enrolled NSCLC cytotoxic chemotherapy. Patients were randomly allocated (1:1) receive docetaxel (60 mg/m2) on day 1 or nab-paclitaxel (100 days 1, 8, 15 a 21-day cycle. The primary end point was overall survival (OS) analyzed an intention-to-treat...

10.1016/j.jtho.2021.03.027 article EN cc-by-nc-nd Journal of Thoracic Oncology 2021-04-27

Aberrant immune responses to viral pathogens contribute pathogenesis, but our understanding of pathological caused by viruses within the human virome, especially at a population scale, remains limited. We analyzed whole-genome sequencing datasets 6,321 Japanese individuals, including patients with autoimmune diseases (psoriasis vulgaris, rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), pulmonary alveolar proteinosis (PAP) or multiple sclerosis) and coronavirus disease 2019...

10.1038/s41588-024-02022-z article EN cc-by-nc-nd Nature Genetics 2025-01-03

PURPOSE To our knowledge, the ACHILLES/TORG1834 trial is first randomized study comparing afatinib and chemotherapy in patients with non–small cell lung cancer (NSCLC) harboring sensitizing uncommon epidermal growth factor receptor ( EGFR ) mutations. METHODS This randomized, open-label was performed at 51 Japanese institutions recruited treatment-naïve nonsquamous NSCLC mutations, excluding exon 20 insertions T790M Patients were randomly assigned 2:1 to receive (30 or 40 mg orally, treating...

10.1200/jco-24-02007 article EN Journal of Clinical Oncology 2025-04-16

A subtraction library was constructed from human insulinoma (beta cell tumor) and glucagonoma (alpha cDNA phagemid libraries. Differential screening of 153 clones with end-labeled mRNAs insulinoma, glucagonoma, HeLa cells resulted in the isolation a novel clone designated IA-1. This has 2838-base pair sequence consisting an open reading frame 1530 nucleotides, which translates into protein 510 amino acids pI value 9.1 molecular mass 52,923 daltons. At 3'-untranslated region there are seven...

10.1016/s0021-9258(18)42173-4 article EN cc-by Journal of Biological Chemistry 1992-07-01

Malignant pleural mesothelioma (MPM) is a fatal thoracic malignancy, the epigenetics of which are poorly defined. We performed high-throughput methylation analysis covering 6,157 CpG islands in 20 MPMs and lung adenocarcinomas. Newly identified genes were further analyzed 50 56 adenocarcinomas via quantitative methylation-specific PCR. Targets histone H3 lysine 27 trimethylation (H3K27me3) genetic alterations also assessed MPM cells by chromatin immunoprecipitation arrays comparative genomic...

10.1158/0008-5472.can-09-1595 article EN Cancer Research 2009-11-04

Hepatocellular carcinoma (HCC) most commonly arises from chronic inflammation due to viral infection, as a result of genetic and epigenetic abnormalities. A global picture changes in HCC is lacking. We used methylated CpG island amplification microarrays (MCAMs) study 6458 islands adjacent preneoplastic tissues [chronic hepatitis (CH) or liver cirrhosis (LC)] comparison with normal where neither infection nor has existed. MCAM identified 719 (11%) prominent genes hypermethylation HCCs. HCCs...

10.1093/carcin/bgn170 article EN Carcinogenesis 2008-07-16

Combination therapy with immune checkpoint inhibitors and cytotoxic chemotherapies (chemoimmunotherapy) is associated significantly better survival outcomes than alone in patients advanced non-small cell lung cancer (NSCLC). However, there are no prognostic markers for chemoimmunotherapy. The nutritional index (PNI) (LIPI) biomarkers inhibitor (ICI) monotherapy or chemotherapies. Thus, we aimed to examine whether these factors could also be We retrospectively examined 237 NSCLC treated In...

10.3390/diagnostics12020423 article EN cc-by Diagnostics 2022-02-06

Background Idiopathic pulmonary fibrosis (IPF) is characterised by worsening dyspnoea and exercise intolerance. Research question Does a long-term rehabilitation improve tolerance in patients with IPF treated standard antifibrotic drugs, which are expected to reduce disease progression? Methods This open-label randomised controlled trial was performed at 19 institutions. Stable receiving nintedanib were into control groups (1:1). The group underwent initial included twice-weekly sessions of...

10.1136/thorax-2022-219792 article EN Thorax 2023-04-03

The Mycoses Forum in Japan has developed management bundles for candidaemia to incorporate into bedside practice. aim of this study was investigate nationwide compliance with the and their impact on clinical outcomes. Non-neutropenic patients treated antifungals were surveyed. Bundles consist nine items complete. Data sent central office between July 2011 April 2012. Six hundred eight analysed. rate achieving all elements 6.9%, it increased 21.4% when analysed by bundle except oral switch....

10.1093/jac/dku414 article EN cc-by-nc Journal of Antimicrobial Chemotherapy 2014-10-17

FLAURA, the prospective trial of osimertinib as a first-line therapy compared with first-generation epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), did not show superior survival benefit for in either subgroup Asians or L858R mutation. In addition, superiority second-generation EGFR-TKI is thus far unclear.We reviewed clinical data all consecutive patients who were treated afatinib between May 2016 and October 2019 from 15 institutions Japan. We defined groups based...

10.1016/j.esmoop.2021.100115 article EN cc-by-nc-nd ESMO Open 2021-05-11

Although previous studies suggest that cancer cachexia is a poor prognostic factor for immune checkpoint inhibitor monotherapy, the impact of on chemoimmunotherapy unclear. We investigated therapeutic outcomes non-small cell lung (NSCLC). retrospectively analyzed patients' medical records with NSCLC who received in 12 institutions Japan between January and November 2019. defined as weight loss exceeding 5% total body or mass index < 20 kg/m2 more than 2% within 6 months before initiation,...

10.1080/2162402x.2021.1950411 article EN cc-by-nc OncoImmunology 2021-01-01

Abstract Pulmonary alveolar proteinosis (PAP) is a devastating lung disease caused by abnormal surfactant homeostasis, with prevalence of 6–7 cases per million population worldwide. While mutations causing hereditary PAP have been reported, the genetic basis contributing to autoimmune (aPAP) has not thoroughly investigated. Here, we conducted genome-wide association study aPAP in 198 patients and 395 control participants Japanese ancestry. The common variant, rs138024423 at 6p21,...

10.1038/s41467-021-21011-y article EN cc-by Nature Communications 2021-02-15

Bovine beta-lactoglobulin (BLG) variant A has been expressed in the methylotropic yeast Pichia pastoris by fusion of cDNA to sequence coding for alpha-mating factor prepro-leader peptide from Saccharomyces cerevisiae. P. Mut+ transformants were obtained single cross-over integration BLG-containing vector into AOX1 locus. In a fed-batch fermenter, cell density approximately 300 mg/ml was achieved controlled glycerol feeding total 24 h. After 72 h methanol induction, secreted BLG reached...

10.1093/protein/10.11.1339 article EN Protein Engineering Design and Selection 1997-11-01

Activating mutations of EGFR are found frequently in a subgroup patients with non‐small cell lung cancer (NSCLC) and highly correlated the response to gefitinib erlotinib. In present study, we searched for , HER2 KRAS 264 resected primary NSCLC from Japanese determined whether there is correlation between genetic alterations these genes clinicopathological factors, together 85 tumors that reported previously. were 102 total 349 tumors, seven had two missense mutations. Reverse...

10.1111/j.1349-7006.2006.00233.x article EN Cancer Science 2006-06-09

Abstract Purpose: The addition of cytotoxic chemotherapy to immune-checkpoint inhibitor (ICI) may enhance antitumor effects. We conducted an open-label randomized phase II/III study evaluate nivolumab + docetaxel combination therapy in comparison with monotherapy for previously treated ICI-naïve non–small cell lung cancer (NSCLC). Patients and Methods: primary endpoint the III was overall survival (OS), secondary endpoints included progression-free (PFS), response rate (ORR), toxicity. As...

10.1158/1078-0432.ccr-22-1687 article EN cc-by-nc-nd Clinical Cancer Research 2022-08-18

Although osimertinib is a promising therapeutic agent for advanced epidermal growth factor receptor (EGFR) mutation-positive lung cancer, the incidence of pneumonitis particularly high among Japanese patients receiving drug. Furthermore, safety and efficacy subsequent anticancer treatments, including EGFR-tyrosine kinase inhibitor (TKI) rechallenge, which are to be administered after recovery, remain unclear. This study investigated EGFR-TKI rechallenge in who experienced first-line...

10.1007/s11523-024-01048-x article EN cc-by-nc Targeted Oncology 2024-04-13
Coming Soon ...